Active, not recruitingNCT04632953
Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program
Studying 3-hydroxyacyl-CoA dehydrogenase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ultragenyx Pharmaceutical Inc
- Principal Investigator
- Medical DirectorUltragenyx Pharmaceutical Inc
- Intervention
- No Intervention(other)
- Enrollment
- 150 enrolled
- Eligibility
- All sexes
- Timeline
- 2021 – 2035
Study locations (16)
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- University of California San Francisco, San Francisco, California, United States
- Children's Hospital of Colorado, Aurora, Colorado, United States
- University of South Florida, Tampa, Florida, United States
- The Emory Clinic, Atlanta, Georgia, United States
- Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Columbia University, New York, New York, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
- University of Utah, Salt Lake City, Utah, United States
- Seattle Children's Hospital, Seattle, Washington, United States
- University of Alberta, Edmonton, Alberta, Canada
- CHEO (Children's Hospital Eastern Ontario), Ottawa, Ontario, Canada
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04632953 on ClinicalTrials.govOther trials for 3-hydroxyacyl-CoA dehydrogenase deficiency
Additional recruiting or active studies for the same condition.
See all trials for 3-hydroxyacyl-CoA dehydrogenase deficiency →